SCHEMBL300024

SCHEMBL300024

CC(C)OC(=O)N1CCC(Oc2cc(N3CCc4cc(S(=O)(=O)CCO[Si](C)(C)C(C)(C)C)ccc43)ncn2)CC1

nearest known ligand 0.73

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 20/20 0.73
CYP2C9 P11712 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238729 0.89 GPR119 (0.81) GPR119CYP2C9
SCHEMBL287689 0.89 GPR119 (0.81) GPR119CYP2C9
SCHEMBL3236483 0.88 GPR119 (0.85) GPR119CYP2C9
SCHEMBL3240476 0.86 GPR119 (0.82) GPR119CYP2C9
SCHEMBL758161 0.86 GPR119 (0.64) GPR119
SCHEMBL3238847 0.86 GPR119 (0.81) GPR119CYP2C9
SCHEMBL3238635 0.85 GPR119 (0.86) GPR119CYP2C9
SCHEMBL300023 0.85 GPR119 (0.54) GPR119
SCHEMBL288614 0.85 GPR119 (1.00) GPR119CYP2C9
SCHEMBL3241962 0.84 GPR119 (0.86) GPR119CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427450-A1 GPR 119 MODULATORS Pfizer Inc. (US) 2012-03-14 EP disclosed
EP-2427448-A1 Gpr 119 modulators Pfizer Inc. (US) 2012-03-14 EP disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052130-A1 GPR 119 MODULATORS GPR119, GPR39, GPR65 GPR119 1/4885CYP2C9 722/4885
US-20100285145-A1 GPR 119 MODULATORS GPR119, GPR65, GPR39 GPR119 1/4885CYP2C9 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.